Alembic Pharmaceuticals Limited delivered robust financial results for the first quarter of fiscal 2027, with consolidated net profit rising 12% to ₹175.33 crore compared to ₹156.53 crore in the corresponding quarter of the previous year. According to the company's exchange filing on Monday, August 4, the pharmaceutical company demonstrated strong operational performance across key metrics during the April to June quarter. The Board of Directors approved the consolidated and standalone unaudited financial results during a meeting held on August 4, 2026, with the meeting commencing at 12:00 noon and concluding at 1:55 p.m. The consolidated earnings per share (EPS) for Q1 FY27 were ₹8.80, a rise from ₹7.85 in Q1 FY26, reflecting improved profitability per share. Managing Director Pranav Amin told Moneycontrol that the company has started FY27 on a strong note, with growth led by healthy volumes, fresh launches and execution across key markets.
The company's US formulation business surged 49% year-on-year to ₹778 crore in the April to June quarter, supported by six to seven product launches, including Alembic's sole 180-day exclusivity for Bosutinib 100 mg and 500 mg tablets used to treat certain forms of cancer. According to Amin, the exclusivity period runs until November 2025, with the September quarter expected to be the first full quarter to benefit from Bosutinib sales in the US. The exclusivity product contributed only one month of sales during the June quarter, indicating a stronger contribution in the current quarter. However, Amin cautioned that pricing could decline sharply once additional competitors enter the market after the exclusivity period ends. The company launched seven products in the US during the quarter and expects around 15 more launches during the remainder of FY27. The core US business, excluding Bosutinib, has also been growing at around 25%, supported by recent launches and market share gains.
The company's revenue surged 26% year-on-year to ₹2,150 crore in the April to June quarter, demonstrating strong momentum across all business segments. The API business grew 33% year-on-year to ₹346 crore, while the ex-US generics business rose 17% to ₹383 crore. The company also received 10 ANDA approvals during the quarter. Beyond the US, other businesses posted healthy growth, with the India branded business seeing 7% growth to ₹642 crore, where the gastroenterology, gynaecology and ophthalmology franchises registered double-digit growth. The animal health business was another bright spot, growing 24% during the quarter and continuing to outperform the broader market. The company's total consolidated income for the quarter reached ₹2,164.70 crore, compared to ₹1,717.22 crore in Q1 FY26.
Reflecting the stronger outlook, Alembic has revised its US growth guidance upward from the initial projection of low double-digit growth of around 10-12% for FY27. The company now expects the US business to grow in the mid-to-high teens for the full year, with Amin indicating that even the revised guidance remains conservative. The stronger US outlook comes at a time when all of Alembic's manufacturing facilities have valid Establishment Inspection Reports (EIRs) from the US Food and Drug Administration, removing a key regulatory overhang and supporting future product approvals and launches. The company's EBITDA increased 18.6% to ₹333 crore in the quarter under review compared to ₹280.5 crore in the corresponding quarter of the previous year, though the EBITDA margin contracted to 15.5% from 16.4% on a year-on-year basis.
In India, where Alembic has lagged industry growth in recent years, management believes a turnaround is underway. Amin said leadership changes have been made in the human health business to address execution gaps, which he identified as the primary reason for the company's earlier underperformance rather than any weakness in its product portfolio. He expects the improvement to become visible from the September quarter onwards. The consolidated financial results for the quarter ended 30 June 2026 were reviewed by KKC & Associates LLP, Chartered Accountants, who issued an unmodified conclusion on the results. The company's total consolidated expenses increased to ₹1,943.23 crore in Q1 FY27, from ₹1,526.67 crore in the prior-year quarter, reflecting increased operational activities and business expansion.
